Dr. Bruix Discusses the Updated Findings of the RESORCE Trial in HCC

Jordi Bruix, MD
Published: Thursday, Jun 29, 2017



Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma (HCC).

The updated overall survival results for the phase III RESORCE trial of regorafenib (Stivarga) were presented at the 2017 World Congress on Gastrointestinal Cancer.

This longer follow-up has confirmed that regorafenib is an effective treatment for patients with HCC who have progressed on sorafenib (Nexavar).

<<< View more from the 2017 World Congress on GI Cancer


Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma (HCC).

The updated overall survival results for the phase III RESORCE trial of regorafenib (Stivarga) were presented at the 2017 World Congress on Gastrointestinal Cancer.

This longer follow-up has confirmed that regorafenib is an effective treatment for patients with HCC who have progressed on sorafenib (Nexavar).

<<< View more from the 2017 World Congress on GI Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x